Denintuzumab mafodotin
Denintuzumab mafodotin
Denintuzumab mafodotin (pronunciation: den-in-tuz-oo-mab maf-oh-doe-tin) is a monoclonal antibody designed for the treatment of cancer.
Etymology
The name "Denintuzumab mafodotin" is derived from the following components: "Denin" refers to the target antigen, CD30; "tuzumab" is a standard suffix for humanized antibodies; and "mafodotin" refers to the drug's payload, monomethyl auristatin F (MMAF), which is attached to the antibody via a linker.
Function
Denintuzumab mafodotin binds to the CD30 antigen, which is commonly expressed on the surface of Hodgkin lymphoma cells and some T-cell lymphomas. Once bound, the drug is internalized by the cancer cell, where the cytotoxic agent MMAF is released to kill the cell.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- CD30: A protein found on the surface of some cells that can be a target for cancer therapy.
- Hodgkin lymphoma: A type of lymphoma in which cancer originates from a specific type of white blood cells called lymphocytes.
- T-cell lymphoma: A type of lymphoma that begins in T cells.
- Monomethyl auristatin F (MMAF): A synthetic antineoplastic agent. It is a potent inhibitor of cell division and growth, which makes it effective in the treatment of certain types of cancer.
External links
- Medical encyclopedia article on Denintuzumab mafodotin
- Wikipedia's article - Denintuzumab mafodotin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski